<SEC-DOCUMENT>0001279569-18-001180.txt : 20180529
<SEC-HEADER>0001279569-18-001180.hdr.sgml : 20180529
<ACCEPTANCE-DATETIME>20180529144822
ACCESSION NUMBER:		0001279569-18-001180
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20180529
FILED AS OF DATE:		20180529
DATE AS OF CHANGE:		20180529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		18863950

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolyticsform6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16</B></P>

<P STYLE="font: 12pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center">For the month of       May 2018</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center">Commission File Number 000-31062</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 24pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Oncolytics Biotech Inc.</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 24pt/normal Times New Roman,serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><I>(Translation of registrant&rsquo;s name into
English)</I></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Suite&nbsp;210, 1167 Kensington Crescent NW</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>Calgary, Alberta, Canada T2N 1X7</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B><I>(Address
of principal executive offices)</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark whether the registrant files or will file
annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 49%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits
the submission in paper of a Form&nbsp;6-K if submitted solely to provide an attached annual report to security holders.</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits
the submission in paper of a Form&nbsp;6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&rsquo;s &ldquo;home country&rdquo;), or under the rules of the home country exchange on which the registrant&rsquo;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant&rsquo;s security holders, and, if discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under
the Securities Exchange Act of 1934.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 49%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Yes&nbsp;&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%; font-family: Wingdings"><FONT STYLE="font: 10pt Times New Roman,serif">No
<FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid"><P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBIT</B></FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NUMBER</B></FONT></P></TD>
    <TD STYLE="width: 2%; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; line-height: 115%; font-family: Calibri,sans-serif; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION</B></FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center; line-height: 115%; font-family: Calibri,sans-serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm">News
    Release Dated May 16, 2018 - Oncolytics Biotech&reg; Announces Publication of REOLYSIN&reg;&nbsp;Abstract<BR>
for the ASCO 2018 Annual Meeting</A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center; line-height: 115%; font-family: Calibri,sans-serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex992.htm">99.2</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex992.htm">News
    Release Dated May 17,  2018 - Oncolytics Biotech<SUP>&reg;</SUP> Announces Collaboration with Merck and Northwestern University Combining
Keytruda<SUP>&reg;</SUP> and REOLYSIN<SUP>&reg; </SUP>in a Phase 2 Second Line Pancreatic Cancer Study </A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center; line-height: 115%; font-family: Calibri,sans-serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex993.htm">99.3</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex993.htm">News Release Dated May 22, 2018 - Oncolytics Biotech<SUP>&reg;</SUP> Has Applied to List its Common Shares on Nasdaq and Announces Share Consolidation</A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center; line-height: 115%; font-family: Calibri,sans-serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ex994.htm">99.4</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex994.htm">News Release Dated May 25, 2018 - Oncolytics Biotech<SUP>&reg;</SUP> Announces Research Collaboration with the Keck School of Medicine of USC
Combining REOLYSIN<SUP>&reg;</SUP> with Keytruda<SUP>&reg;</SUP>, Velcade<SUP>&reg;</SUP> and Dexamethasone</A></FONT></TD></TR>
<TR>
    <TD STYLE="text-align: center; line-height: 115%; font-family: Calibri,sans-serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex995.htm">99.5</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex995.htm">News Release Dated May 29, 2018 - Oncolytics Biotech<SUP>&reg;</SUP> Announces New OTCQX Ticker Symbol</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 11pt">
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"><B>Oncolytics Biotech Inc.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">(Registrant)</P></TD></TR>
<TR>
    <TD STYLE="width: 50%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 5%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="width: 45%; line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">&nbsp;Date:&nbsp;&nbsp;
          May 29, 2018</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">By:</FONT></TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman,serif">/s/&nbsp;&nbsp;Kirk Look</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Kirk Look</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-family: Calibri,sans-serif"><FONT STYLE="font: 10pt Times New Roman,serif">Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman,serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 16, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>



<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oncolytics Biotech&reg; Announces Publication
of REOLYSIN&reg;&nbsp;Abstract </B><BR>
<B>for the ASCO 2018 Annual Meeting</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALGARY, AB and SAN DIEGO, CA, May 16, 2018
--</B> Oncolytics Biotech<SUP>&reg;</SUP> Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN<SUP>&reg;</SUP> (pelareorep),
an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced publication of an abstract on pelareorep
for the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting. The meeting will take place from June 1 - 5, 2018 at
McCormick Place, Chicago, IL.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The abstract, authored by Wilkinson&nbsp;et
al., &quot;Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade
therapy&quot;, outlines results of a study assessing whether pelareorep promotes a predictive inflamed tumor phenotype that correlates
with a response to immunotherapy in breast cancer (BC), colorectal cancer (CRC), hepatocellular carcinoma (HCC) and non-small cell
lung cancer (NSCLC). The results suggest that all cell lines are susceptible to pelareorep&rsquo;s induced cytopathic effect. In
particular, BC and HCC cells lines had a significantly inflamed phenotype and also upregulated key chemokines known to promote
response to immunotherapy.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;These results clearly demonstrate that
viral priming in both BC and HCC tumors can activate interferon gamma-related gene expression which both upregulates checkpoint
ligands on tumor cells and promotes activation and infiltration of lymphocytes into the tumor,&rdquo; said Dr. Matt Coffey, President
and CEO of Oncolytics Biotech. &ldquo;They also support the hypothesis that the virus is engaging a dramatic immune response against
the tumor in our recent mBC trial but also suggests that the virus may very well act as a backbone for checkpoint blockage by promoting
an inflamed phenotype in the tumor microenvironment.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The complete Abstract can be found online at
https://am.asco.org/. Full details from the poster presentation will be announced when it is being presented on Monday, June 4
from 8:00 &ndash; 11:30 in Hall A, poster board #303.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About REOLYSIN/Pelareorep&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REOLYSIN, also known as pelareorep, is a non-pathogenic,
proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment
of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype
through innate and adaptive immune responses to treat a variety of cancers.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oncolytics is a biotechnology company developing
REOLYSIN<SUP>&reg;</SUP>, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype -- turning &quot;cold&quot; tumors &quot;hot&quot; -- through innate and
adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and
adaptive immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well
as studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies.
For further information, please visit: <U>www.oncolyticsbiotech.com</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information
under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred
to herein as &ldquo;forward-looking statements&rdquo;). Forward-looking statements, including the Company's belief as to the potential
and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated
developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as
a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable laws.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Company Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Michael Moore</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations &amp; Corporate Communications</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-886-7813</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>mmoore@oncolytics.ca</U></P>
        <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Robert Uhl</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Westwicke Partners</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-356-5932<BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>robert.uhl@westwicke.com</U></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Jason Spark</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Canale Communications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
        619-849-6005</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>jason@canalecomm.com</U></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>



<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 17, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.2</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oncolytics Biotech<SUP>&reg;</SUP> Announces
Collaboration with Merck and Northwestern</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>University Combining Keytruda<SUP>&reg;</SUP> and REOLYSIN<SUP>&reg; </SUP>in a</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Phase
2 Second Line Pancreatic Cancer Study </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALGARY, AB and SAN DIEGO, CA, May 17, 2018
--</B> Oncolytics Biotech<SUP>&reg;</SUP> Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN<SUP>&reg;</SUP> (pelareorep),
an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced an investigator sponsored study (IST)
supported by Merck Inc. (Merck), Northwestern University (Northwestern) and Oncolytics. This study is an extension of the previously
reported phase 1 study (REO 024) that will investigate pelareorep in combination with Merck&rsquo;s anti-PD1 checkpoint inhibitor
Keytruda<SUP>&reg;</SUP>, to treat second line pancreatic cancer patients. The study, run by the principal investigator of REO
024, Dr. Devalingham Mahalingam, will plan to enroll approximately 40 patients with advanced pancreatic cancer and will be conducted
at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&quot;This study using Merck&rsquo;s Keytruda
is our second I-O combination in human trials after our multiple myeloma study in combination with Celgene&rsquo;s Imnovid and
Revlimid,&quot; said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. &quot;We&rsquo;re very happy with Merck&rsquo;s
increased involvement in our pancreatic studies and believe combining pelareorep with Keytruda poses an exciting opportunity to
lay additional groundwork towards our ultimate goal &ndash; to expand the use of check point inhibitors as anti-cancer agents by
promoting an inflamed phenotype in the tumor, or turning cold tumors hot.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;REO 024, a phase 1b study combining&nbsp;pelareorep&nbsp;and&nbsp;Keytruda&nbsp;in
second line pancreatic patients, was designed to evaluate safety and tolerability of the combination,&rdquo; said Dr.&nbsp;Mahalingam,
Associate Professor of Medicine (Hematology and Oncology),&nbsp;Northwestern&nbsp;University Feinberg School of Medicine.&nbsp;&ldquo;The
results from that study demonstrated that the combination is safe, but also that there was early evidence of clinical activity,
including one patient that had&nbsp;a&nbsp;partial response lasting 17.4 months and two with stable disease of 126 days and 277
days. This&nbsp;new phase two&nbsp;study will enroll patients with advanced pancreatic cancer failing front line chemotherapy and
will primarily evaluate overall response rate of the combination therapy. The study will also provide important biomarker data
determined by analysis of pre- and post-treatment biopsies and blood-based immune markers.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #1F497D">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Final study design and other details will be
announced upon enrollment of the first patient, expected in the third quarter 2018.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About REOLYSIN/Pelareorep&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REOLYSIN, also known as pelareorep, is a non-pathogenic,
proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment
of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype
through innate and adaptive immune responses to treat a variety of cancers.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oncolytics is a biotechnology company developing
REOLYSIN<SUP>&reg;</SUP>, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype -- turning &quot;cold&quot; tumors &quot;hot&quot; -- through innate and
adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and
adaptive immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well
as studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies.
For further information, please visit: <U>www.oncolyticsbiotech.com</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information
under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred
to herein as &ldquo;forward-looking statements&rdquo;). Forward-looking statements, including the Company's belief as to the potential
and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated
developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as
a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable laws.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Company Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Michael Moore</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations &amp; Corporate Communications</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-886-7813</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>mmoore@oncolytics.ca</U></P>
        <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Robert Uhl</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Westwicke Partners</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-356-5932<BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>robert.uhl@westwicke.com</U></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Jason Spark</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Canale Communications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
        619-849-6005</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>jason@canalecomm.com</U></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;</FONT></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 22, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.3</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oncolytics Biotech<SUP>&reg;</SUP> Has Applied
to List its Common Shares on Nasdaq</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>and Announces Share Consolidation </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALGARY, AB and SAN DIEGO, CA, May 22, 2018
--</B> Oncolytics Biotech<SUP>&reg;</SUP> Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN<SUP>&reg;</SUP> (pelareorep),
an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it has applied to list its common
shares on the&nbsp;Nasdaq Capital Market&nbsp;(&ldquo;Nasdaq&rdquo;). In connection with the planned U.S. listing, and as previously
authorized by its shareholders, the Corporation is implementing a consolidation of its outstanding common shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&quot;Over the past 18 months we have advanced
the development of pelareorep,&rdquo; said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. &ldquo;Pelareorep, in combination
with paclitaxel, demonstrated an almost doubling of median overall survival in our target patient population in a phase two metastatic
breast cancer study, we received Fast Track Designation and reached agreement on a special protocol assessment with the FDA to
run a phase three registration study in metastatic breast cancer. From a business development perspective, we announced two immuno-oncology
combination studies with Merck and Celgene, along with a regional partnering transaction with Adlai Nortye. With these milestones
achieved we believe we are now ready to list our common shares on Nasdaq, one of our stated strategic objectives.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Corporation's board of directors has determined
that the consolidation will be done on the basis of one new common share for every 9.5 currently outstanding common shares. The
consolidation will be effective on May 22, 2018 and the common shares are expected to begin trading on a post-consolidation basis
on both the TSX and OTCQX as of market open on May 25, 2018. There are currently 142,396,222 common shares issued and outstanding,
and it is expected that there will be 14,989,076 common shares issued and outstanding following the consolidation, subject to rounding
for any fractional shares. No fractional shares will be issued as a result of the share consolidation. Fractional interests will
be rounded down to the nearest whole number of common shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Registered shareholders holding share certificates
will be mailed a letter of transmittal advising of the share consolidation and instructing them to surrender their share certificates
representing pre-consolidation common shares for replacement certificates or direct registration advice representing their post-consolidation
common shares. Until surrendered for exchange, following the effective date of the consolidation, each share certificate formerly
representing pre-consolidation common shares will be deemed to represent the number of whole post-consolidation common shares to
which the holder is entitled as a result of the consolidation.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of common shares of the Corporation
who hold uncertificated common shares (that is common shares held in book-entry form and not represented by a physical share certificate),
either as registered holders or beneficial owners, will have their existing book-entry account(s) electronically adjusted by the
Corporation's transfer agent or, for beneficial shareholders, by their brokerage firms, banks, trusts or other nominees that hold
in street name for their benefit. Such holders do not need to take any additional actions to exchange their pre-consolidation common
shares for post-consolidation common shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Beneficial shareholders holding their common
shares through a bank, broker or other nominee should note that such banks, brokers or other nominees may have different procedures
for processing the consolidation than those that have been put in place by the Corporation for registered shareholders. If you
hold your common shares with such a bank, broker or other nominee, and if you have questions in this regard, you are encouraged
to contact your nominee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The listing of the Corporation's common shares
on the Nasdaq Capital Market remains subject to the approval of that exchange and the satisfaction of applicable listing requirements</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oncolytics is a biotechnology company developing
REOLYSIN<SUP>&reg;</SUP>, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype -- turning &quot;cold&quot; tumors &quot;hot&quot; -- through innate and adaptive
immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and
adaptive immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well as
studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information
under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred
to herein as &ldquo;forward-looking statements&rdquo;). Forward-looking statements, including the Company's belief as to the potential
and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; a potential listing of the common shares on
Nasdaq, the consolidation of the common shares, the timing of trading of the common shares on a post-consolidation basis on the
TSX and OTCQX and other statements related to anticipated developments in the Company's business and technologies involve known
and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and
development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable
laws.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Company Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Michael Moore</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations &amp; Corporate Communications</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-886-7813</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>mmoore@oncolytics.ca</U></P>
        <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Robert Uhl</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Westwicke Partners</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-356-5932<BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>robert.uhl@westwicke.com</U></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Jason Spark</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Canale Communications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
        619-849-6005</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>jason@canalecomm.com</U></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 25, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.4</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oncolytics Biotech<SUP>&reg;</SUP> Announces
Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN<SUP>&reg;</SUP> with Keytruda<SUP>&reg;</SUP>,
Velcade<SUP>&reg;</SUP> and Dexamethasone</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALGARY, AB and SAN DIEGO, CA, May 25, 2018
--</B> Oncolytics Biotech<SUP>&reg;</SUP> Inc. (TSX: ONC) (OTCQX: ONCYF), currently developing REOLYSIN<SUP>&reg;</SUP> (pelareorep),
an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a collaboration with the Keck School
of Medicine of University of Southern California (USC) using pelareorep in combination with Keytruda<SUP>&reg;</SUP>, Velcade<SUP>&reg;</SUP>
and dexamethasone, to treat multiple myeloma. This study, facilitated by Dr. Kevin Kelly, Associate Professor of Clinical Medicine,
is an extension of the current REO 019 study evaluating pelareorep in combination with Velcade and dexamethasone to treat multiple
myeloma and will be conducted at the USC Norris Comprehensive Cancer Center. It will add Keytruda, Merck&rsquo;s anti PD-1 therapy,
to the regimen.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The study continues to build on the Company&rsquo;s
I-O program and is now its third combination in human trials after the previously announced second line pancreatic cancer study
&ndash; also with Keytruda &ndash; and the multiple myeloma study in combination with Celgene&rsquo;s Imnovid<SUP>&reg;</SUP> and
Revlimid<SUP>&reg;</SUP>. Oncolytics will supply pelareorep for the study and Merck will supply the Keytruda.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The combination of proteasome inhibitors and
pelareorep has been demonstrated to increase PD-L1 expression on multiple myeloma cells and to recruit T-cells to the bone marrow.
This&nbsp;study will enroll patients with relapsed-refractory multiple myeloma and will primarily evaluate overall response rate,
as well as safety and tolerability. It will also provide important biomarker data determined by analysis of pre- and post-treatment
biopsies and blood-based immune markers.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Final study design and other details will be
announced upon enrollment of the first patient, expected in the second half of 2018.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About REOLYSIN/Pelareorep&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REOLYSIN, also known as pelareorep, is a non-pathogenic,
proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment
of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype
through innate and adaptive immune responses to treat a variety of cancers.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oncolytics is a biotechnology company developing
REOLYSIN<SUP>&reg;</SUP>, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype -- turning &quot;cold&quot; tumors &quot;hot&quot; -- through innate and adaptive
immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and
adaptive immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well as
studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information
under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred
to herein as &ldquo;forward-looking statements&rdquo;). Forward-looking statements, including the Company's belief as to the potential
and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; the collaboration between Merck and USC using
pelareorep, including the timing, enrollment and potential benefits to the Company thereof; and other statements related to anticipated
developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as
a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable laws.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Company Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Michael Moore</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations &amp; Corporate Communications</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-886-7813</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>mmoore@oncolytics.ca</U></P>
        <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Robert Uhl</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Westwicke Partners</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-356-5932<BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>robert.uhl@westwicke.com</U></FONT></P></TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Jason Spark</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Canale Communications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
        619-849-6005</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>jason@canalecomm.com</U></P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>6
<FILENAME>ex995.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 29, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.5</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B><IMG SRC="image_001.jpg" ALT=""></B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B></B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oncolytics Biotech<SUP>&reg;</SUP> Announces
New OTCQX Ticker Symbol </B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CALGARY, AB and SAN DIEGO, CA, May 29, 2018
--</B> Oncolytics Biotech<SUP>&reg;</SUP> Inc. (TSX: ONC) (OTCQX: ONCYD), currently developing REOLYSIN<SUP>&reg;</SUP> (pelareorep),
an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that following its share consolidation,
the Company&rsquo;s new ticker symbol on the OTCQX is ONCYD.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Oncolytics Biotech Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oncolytics is a biotechnology company developing
REOLYSIN<SUP>&reg;</SUP>, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype -- turning &quot;cold&quot; tumors &quot;hot&quot; -- through innate and
adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and
adaptive immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well
as studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies.
For further information, please visit: <U>www.oncolyticsbiotech.com</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>This press release contains forward-looking
statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information
under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred
to herein as &ldquo;forward-looking statements&rdquo;). Forward-looking statements, including the Company's belief as to the potential
and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated
developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as
a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize
pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable laws.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Company Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Michael Moore</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Vice President, Investor Relations &amp; Corporate Communications</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-886-7813</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>mmoore@oncolytics.ca</U></P>
        <P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Robert Uhl</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Westwicke Partners</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">858-356-5932<BR>
        <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>robert.uhl@westwicke.com</U></FONT></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Media Contact</B></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Jason Spark</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Canale Communications&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
        619-849-6005</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><U>jason@canalecomm.com</U></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 -4# 2(  A$! Q$!_\0
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M^*?[,/[1O[5/_!%/]K[X??L!?MW?%#7/C7^PM\?M>F\*?L/?M>>,WN=2\5^
M/$\NH6<.C_!#XU^(A;QQ(DO]I1Z98:CJ4TEAH:+I&HZ%=V'@*?7=&^&G]C+!
M6!# $8.00#_.OR%_X+0_L6>%OVV?V!/VAO@]JMCO\36W@G5_B)\*M5@11?\
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MP[X5\3_VQI.JEO".K_\ "57G]LKI1TW63]GMOL6IVO[W?V7[8G['?P"_;N^
MGC#]F_\ :2\&#QI\,_&)TZ[GMK;4K_0]<T+7=$O$U#0/%/A?Q!I<L.HZ'XBT
M.^C6XLKZV<QSQ/<Z9J5O?Z/J&HZ?= 'TM#)%'%%'Y@.U5C!&3DJ%'.T$+C<"
MV<!1G. K8_);_@IA^P%\9_VG?B/^R=^U7^R5\<O#?P,_;(_8BUCXJZM\%]1^
M)?A(^./@SXXT#XT^&M(\(?$SP!\3-&M0VNZ5IOB/0-%@TR'Q9X7CNM?T2RO=
M8;3=/DU6;2M8T#QKP-_P19^(_A35? VA:W_P5Q_X*;^-?@;\-/$?A;Q'X/\
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M?>)]#\&:#\'93"TQ^(5M?[M#32)I?[-O&_B:V\%^"_%_C&]MY[NS\)^%]?\
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
